ESR1 and neoplasm: The PEPI score was used as the primary endpoint in this study, which includes tumor size, lymph node status, Ki67 expression level, and ER status.20 The P024 study demonstrated varying long-term recurrence risks in different PEPI score subgroups,20 and this finding was subsequently confirmed in the prospective study IMPACT.21 The findings showed that 15% of patients (3/20) achieved PEPI 0 scores, suggesting that the combination of tucidinostat with exemestane might bring a potential long-term beneficial effect for those patients.